- Home
- GILD
GILD
Gilead Sciences Inc.
as 09-05-2025 4:00pm EST
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 144.1B | IPO Year: | 1992 |
| Target Price: | $115.68 | AVG Volume (30 days): | 5.9M |
| Analyst Decision: | Buy | Number of Analysts: | 23 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 5.01 | EPS Growth: | 496.80 |
| 52 Week Low/High: | $77.74 - $121.83 | Next Earning Date: | 11-05-2025 |
| Revenue: | $28,863,000,000 | Revenue Growth: | 3.81% |
| Revenue Growth (this year): | 2.01% | Revenue Growth (next year): | 4.03% |
Stock Insider Trading Activity of Gilead Sciences Inc. (GILD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| O'Day Daniel Patrick | GILD | Chairman & CEO | Aug 28 '25 | Sell | $113.63 | 10,000 | $1,136,300.00 | 595,725 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Aug 15 '25 | Sell | $118.53 | 2,500 | $296,325.00 | 160,110 | |
| Mercier Johanna | GILD | Chief Commercial Officer | Aug 15 '25 | Sell | $118.74 | 28,000 | $3,318,926.70 | 117,168 | |
| Dickinson Andrew D | GILD | Chief Financial Officer | Jun 16 '25 | Sell | $110.17 | 2,500 | $275,425.00 | 160,110 | |
| Mercier Johanna | GILD | Chief Commercial Officer | Jun 16 '25 | Sell | $110.17 | 3,000 | $330,510.00 | 117,168 |
Latest Gilead Sciences Inc. News
GILD Breaking Stock News: Dive into GILD Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Gilead Acquires Interius BioTherapeutics to Advance Next-Gen Cell Therapy
Pharmaceutical Technology
2 days ago
Gilead Sciences advances HIV prevention with new US partnership
Associated Press Finance
2 days ago
The US will buy 2 million doses of an HIV prevention drug for low-income countries
MT Newswires
2 days ago
Gilead Sciences Collaborates With PEPFAR to Make HIV Drug Lenacapavir Accessible Across Countries
Business Wire
2 days ago
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
Insider Monkey
2 days ago
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
GlobeNewswire
3 days ago
Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer
GlobeNewswire
3 days ago
Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva
Compare GILD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GILD Gilead Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.